Xenon Pharmaceuticals to Present Key Azetukalner Data at AAN 2026
Event summary
- Xenon Pharmaceuticals will present five abstracts at the 2026 AAN Annual Meeting, including Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures.
- Long-term 48-month efficacy and safety data from the X-TOLE open-label extension study will also be shared.
- Real-world data on epilepsy treatment experiences and comorbidities will be presented.
- Early-stage data on the NaV1.1 program in Dravet syndrome will be highlighted.
The big picture
Xenon Pharmaceuticals is positioning itself as a key player in the neuroscience space with a focus on epilepsy and other neurological disorders. The upcoming data presentations at the AAN 2026 Annual Meeting are critical for validating the clinical profile of azetukalner and potentially accelerating its path to market. The company's strategic emphasis on real-world data and long-term efficacy studies underscores its commitment to addressing unmet needs in epilepsy treatment.
What we're watching
- Clinical Efficacy
- How the Phase 3 X-TOLE2 study results will impact the regulatory pathway for azetukalner in focal onset seizures.
- Long-Term Safety
- Whether the 48-month data from the X-TOLE open-label extension study will reveal any long-term safety concerns for azetukalner.
- Market Differentiation
- The pace at which Xenon can leverage real-world data to differentiate azetukalner in the competitive epilepsy treatment landscape.
Related topics